Search Site

Trends banner

SAIB reports $139 million Q1 net profit

its assets increased by 20.08 percent to $43.65bn.

Nissan forecasts $5.3bn annual net loss

Last year, it announced 9,000 job cuts worldwide.

Saudia to acquire 20 wide-body aircraft

10 of these being acquired for its flydaeal low-cost airline

ADIB’s Q1 net profit $517 million

Q1 2025 net profit before tax increased 18% YoY.

Emirates Islamic Q1 profit $394m

The bank's profit crossed AED 1bn mark for the first time.

Avalon sets sights on Tadawul listing

The final Offer Price will be determined at the end of the book-building process. (Avalon)
  • The book-building process for Avalon Pharma's IPO will commence on January 14th and conclude on January 18th.
  • In the event that there is sufficient demand by Individual Investors, the number of shares initially allocated to participating parties will be reduced to 5.4 million shares.

Riyadh, Saudi Arabia — Middle Eastern pharmaceutical firm Avalon Pharma has announced its intention to float on the Saudi Exchange’s main market, offering 6 million shares, representing 30 percent of its issued share capital, in its initial public offering.

The book-building process for Avalon Pharma’s IPO will commence on January 14th and conclude on January 18th.

The company said in a statement that in the event that there is sufficient demand by Individual Investors, the number of shares initially allocated to participating parties will be reduced to 5.4 million shares, representing 90 percent of the total offering.

“This IPO is a historic moment for Avalon Pharma,” said CEO Dr. Omar Hassan.

“The Saudi healthcare sector is experiencing unprecedented growth, and we are confident that our listing on the Tadawul will enable us to capitalize on this momentum. The capital raised will fuel our expansion plans, allowing us to bring more effective and affordable medications to families across the Kingdom,” he said.

Headquartered in Riyadh, Saudi Arabia, the company exports its products to over 10 countries across the Middle East and North Africa and is one of the fastest growing consumer pharma companies in Saudi Arabia.